+44 20 8123 2220
info@marketpublishers.com

CAR T-cell Therapy Market Size, Share & Trends by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target Antigen (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), End User & Region - Global Forecast to 2029

https://marketpublishers.com/r/C3CB780F5397EN.html
Date: July 2024
Pages: 266
Price: US$ 4,950.00 (Single User License)
ID: C3CB780F5397EN

Abstracts

The global CAR T-cell therapy market is estimated to reach USD 29.0 Billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 39.6% during the forecast period of 2024 to 2029. Market growth is driven by the rise in the global cancer prevalence. Technological advancements in CAR T-cell therapies and rising therapy development investment and funding is likely to propel the market growth. However, adverse effects associated with CAR T-cell therapy and high treatment costs are some of the major factors expected to restrain the market growth during the forecast period.

“Yescarta segment accounted for the highest share of 2023.”

Based on product, the CAR T-cell therapy market is broadly segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel) and other products. The Yescarta segment held the largest market share in 2023. Market growth is attributed to high response rates and durable remissions of Yescarta in treating relapsed/refractory cancers leading to an increase in therapy adoption.

“The Hospitals End User segment held the dominant share in the CAR T-cell therapy market.”

+44 20 8123 2220
info@marketpublishers.com

Based on end users, the global CAR T-cell therapy market is segmented into hospitals, long term care facilities and specialty centers. In 2023, the hospitals segment emerged as the primary growth driver in the global CAR T-cell therapy market, with the highest CAGR during the forecast period. Hospitals are incorporating CAR T-cell therapies into their standard oncology treatment protocols. This trend is boosting demand for CAR T-cell treatments as more hospitals embrace these therapies. Furthermore, hospitals play a key role in facilitating clinical trials for CAR T-cell therapies. By actively participating in research initiatives and collaborations with pharmaceutical companies, hospitals contribute to expanding the evidence base and accelerating regulatory approvals, which in turn stimulates market growth.

“Asia Pacific region estimated to show fastest growth rate.”

The CAR T-cell therapy market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. During the forecast period, Asia Pacific region is estimated to grow at the highest CAGR. The supportive regulatory frameworks, rich CAR T-cell therapy product pipeline and expedited approval processes facilitate quicker market entry for innovative therapies, driving growth in the Asia Pacific market. In addition, increasing collaborations between hospitals, universities, and industries in Chinaare expected to provide lucrative market growth. The rapid increase in clinical trials evaluating the safety and effectiveness of CAR T-cell therapy across diverse cancer types in China also signals significant advancements. These studies have demonstrated encouraging results in treating leukemia, lymphoma, and solid tumors, with specific patient cohorts showing substantial rates of complete remission and sustained responses. This trend highlights Asia Pacific’s progress in developing and validating CAR T-cell treatments, positioning the region as a key player in advancing therapeutic outcomes in oncology in CAR T-cell therapy.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70%, and Demand Side - 30%

By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%

By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, MEA- 5%

+44 20 8123 2220
info@marketpublishers.com

List of Companies Profiled in the Report:

Bristol-Myers Squibb Company (US)

Gilead Sciences Inc. (US)

Novartis AG (Switzerland)

Johnson & Johnson (US)

CARsgen Therapeutics Holdings Limited (China)

IASO Biotherapeutics (China)

JW (Cayman) Therapeutics Co. Ltd (China)

ImmunoAct (India)

CRISPR Therapeutics (Switzerland)

Autolus Therapeutics (UK)

Allogene Therapeutics (US)

Cartesian Therapeutics Inc. (US)

Guangzhou Bio-gene Technology Co. Ltd (China)

Wugen (US).

Research Coverage:

This report provides a detailed picture of the CAR T-cell therapy market. It aims to estimate the size and future growth potential of the market across different segments, such as product, target, demographic, indications, end-users and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

+44 20 8123 2220
info@marketpublishers.com

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall CAR T-cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (technological advancements in CAR T-cell therapies, growing cancer prevalence, and rising investment and funding for therapy development), restraints (high therapy costs and adverse effects), opportunities (expansion into solid tumors and collaborations and partnerships) and challenges (patient recruitment for trials and reimbursement issues) are influencing the growth of CAR T-cell therapy market.

Product Development/Innovation: Detailed insights on newly launched products of the CAR T-cell therapy market.

Market Development: Comprehensive information about lucrative markets – the report analyses the CAR T-cell therapy market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CAR T-cell therapy market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), JW (Cayman) Therapeutics Co. Ltd (China), ImmunoAct (India), among others in the CAR T-cell therapy market.

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: CAR T-cell Therapy Market Size, Share & Trends by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target Antigen (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), End User & Region - Global Forecast to 2029

Product link: https://marketpublishers.com/r/C3CB780F5397EN.html

Price: US$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/C3CB780F5397EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

+44 20 8123 2220
info@marketpublishers.com

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970